# Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted

- Link: https://www.thailand-business-news.com/pr-news/key-milestone-achieved-nda-for-sumecigrel-capsule-an-antiplatelet-innovative-drug-by-vcare-pharmatech-officially-accepted
- Published: 2026-06-26T21:30:00+07:00
- Author: PR Newswire

NANJING, China, June 26, 2026 /PRNewswire/ — Recently, the NDA for Sumecigrel Capsule(
formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by
Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted
by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel
antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment
option to tens of millions of patients with cardiovascular and cerebrovascular diseases.

Sumecigrel Capsule is a new-generation oral P2Y12 receptor antagonist, clinically
indicated for the treatment and prevention of atherosclerotic thrombotic events,
including Acute Coronary Syndrome (ACS), Ischemic Stroke (IS) and Peripheral Arterial
Disease (PAD). Designed to address the boxed warning regarding clopidogrel resistance,
this drug innovatively optimizes the metabolic pathway of clopidogrel while retaining
the molecular discovery pathway of its active metabolite. It aims to strike a better
balance between the therapeutic benefits and bleeding risks of antiplatelet medications.

A series of completed clinical studies, including Phase I, Phase II, China-US PK/
PD bridging study and Phase III trials, have fully validated the clinical efficacy
and safety of Sumecigrel Capsule. It boasts multiple advantages including faster
onset of action, lower dosage, more stable therapeutic effect, better control of
bleeding risks, reduced metabolic burden and broader application scope. The Phase
III clinical studies have now been completed. Sumecigrel demonstrated a trend of
superior performance over clopidogrel in reducing the risk of MACCE, with more prominent
benefits observed in elderly patients, those complicated with anemia, chronic kidney
disease and patients undergoing complex PCI with multiple stents, especially high-
risk elderly patients aged 75 and above. The drug also shows favorable safety profiles:
its major bleeding risk is comparable to that of clopidogrel and better than data
from similar studies, with no new unexpected safety signals identified.

Against the backdrop of population aging, clinical challenges such as high bleeding
risks and complicated combined medication use among elderly cardiovascular patients
have become increasingly prominent. Approximately 30% to 40% of patients struggle
to achieve a balance between efficacy and safety, leading to huge unmet clinical
needs. Sumecigrel effectively addresses the shortcomings of existing drugs and offers
a new therapeutic breakthrough for patients with high-risk and complex conditions.

**Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech, stated: **"
Sumecigrel Capsule is an achievement from the industry-university-research cooperation
between our company and China Pharmaceutical University in the early stage. After
years of intensive R&D efforts, the NDA has now been accepted, marking a critical
milestone. The field of cardiovascular and cerebrovascular disease treatment is 
in urgent need of high-quality innovative drugs with balanced efficacy and safety
to cater to increasingly personalized antiplatelet treatment scenarios. We look 
forward to the successful launch of Sumecigrel Capsule to benefit patients with 
cardiovascular and cerebrovascular diseases worldwide."

Following the achievement of this key regulatory milestone in China, Vcare PharmaTech
will fully advance the subsequent review and approval procedures for marketing. 
Meanwhile, the company continues to prepare for marketing applications in the United
States, the European Union and other countries and regions. In addition, Vcare PharmaTech
has entered into an exclusive regional licensing agreement with Everest Medicines
for the Asia-Pacific market of Sumecigrel. The company is accelerating the global
strategic layout of this product in an all-round manner.

**About Sumecigrel**

Sumecigrel is the world’s first new-generation P2Y12 receptor antagonist developed
on the premise of retaining the same active metabolite as clopidogrel and optimizing
its metabolic pathway to mitigate clopidogrel’s heavy reliance on CYP2C19 genetic
polymorphism. It is indicated for atherosclerotic thrombotic events including Acute
Coronary Syndrome (ACS), Ischemic Stroke (IS) and Peripheral Arterial Disease (PAD).
It stands as one of Vcare PharmaTech’s representative achievements under the philosophy
of "differentiated original design to address unmet clinical needs".

The molecular design findings of the drug were published in _Journal of Medicinal
Chemistry (JMC)_, a top journal of the American Chemical Society, and highlighted
by _SciBX_ under Nature Portfolio, being recognized as "one of the most commercially
promising projects in the field of new antiplatelet drugs". Currently, its NDA has
been accepted in China, and NDA preparations are underway in the United States, 
the European Union and other regions. With Best-in-Class potential and broad commercial
prospects, Sumecigrel is poised to reshape the antithrombotic drug market, which
has seen no innovative drugs targeting the same mechanism launched for more than
a decade.

**About Cardiovascular and Cerebrovascular Diseases**

Cardiovascular and cerebrovascular diseases refer to a group of functional and organic
disorders of the circulatory system, covering diseases related to the heart, blood
vessels and neurohumoral systems regulating blood circulation. According to lesion
locations and pathological characteristics, they are generally divided into heart
diseases, cerebrovascular diseases (such as stroke) and peripheral vascular diseases,
forming a multi-level disease spectrum across the whole circulatory system.

Atherosclerosis is the major pathological basis of these diseases. Lipid deposition,
vascular endothelial injury, inflammatory response and thrombosis may cause vascular
stenosis, occlusion or decreased elasticity, further leading to severe conditions
such as myocardial ischemia, myocardial infarction, cerebral infarction and cerebral
hemorrhage. These diseases are featured by high morbidity, disability, mortality,
recurrence rate and numerous complications. Major risk factors include hypertension,
hyperlipidemia, hyperglycemia, smoking, excessive drinking, sedentary lifestyle,
obesity and advanced age. Mostly developing chronically with acute episodes, they
rank as the top chronic diseases threatening the health of middle-aged and elderly
people.

Cardiovascular and cerebrovascular diseases have become one of the leading causes
of death worldwide. The related death toll rose to 17.9 million in 2019, accounting
for about 32% of all global deaths in that year, among which around 85% were caused
by myocardial infarction (a major type of Acute Coronary Syndrome) and stroke. The
latest epidemiological studies show that the death toll from cardiovascular and 
cerebrovascular diseases further increased to 19.2 million in 2023.

[⌊Vcare PharmaTech Innovative Drug Pipeline⌉⌊Vcare PharmaTech Innovative Drug Pipeline⌉[
Vcare PharmaTech
Innovative Drug Pipeline

**About Vcare PharmaTech**

Founded in 2010 by professors from China Pharmaceutical University and overseas 
returnee talents, Jiangsu Vcare PharmaTech Co.,Ltd. is a commercial-stage innovative
bio-pharmaceutical enterprise empowered by AI for differentiated original drug design.
The company is dedicated to the development of innovative drugs and cutting-edge
therapies.

Headquartered in the Biomedical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech
owns a 21,000 square-meter intelligent R&D headquarters. It has built a full-chain
innovation system for independent drug R&D and industrialization, covering AI-driven
differentiated project initiation, preclinical candidate discovery, integrated drug
development and green manufacturing. The company boasts a strong talent team of 
more than 900 employees, over 84% of whom are technical staff, including more than
200 talents with master’s and doctoral degrees. This high-caliber, professional 
and innovative core R&D team underpins the company’s continuous technological breakthroughs
and product iteration.

Over sixteen years of dedication to pharmaceutical innovation, Vcare PharmaTech 
adheres to the core strategy of independent R&D and focuses on addressing unmet 
clinical needs via differentiated approaches. Centering on overcoming treatment 
resistance, tackling drug resistance and optimizing target selectivity, the company
has established a diversified and high-quality pipeline of innovative drugs covering
major chronic disease areas including cardiovascular and cerebrovascular diseases,
inflammatory and autoimmune diseases, as well as oncology.

Eratrectinib Capsule, a new-generation TRK inhibitor, is clinically used for patients
with solid tumors harboring NTRK gene fusions. It delivers a high tumor response
rate and strong anti-resistance performance and has been approved for marketing.
Sumecigrel Capsule, a new-generation oral P2Y12 receptor antagonist targeting clopidogrel
resistance, has had its NDA accepted in China. VC005, a new-generation highly selective
JAK1 inhibitor focusing on inflammatory and autoimmune diseases, is in Phase III
clinical trials for atopic dermatitis with both oral and topical formulations developed
for all patient groups. It is also being explored for ankylosing spondylitis, vitiligo,
alopecia areata and other autoimmune diseases, with promising efficacy and safety
data.

Leveraging years of technological accumulation, Vcare PharmaTech strives to integrate
AI capabilities across the entire R&D and production chain, and has established 
an AI-powered advanced drug R&D system and professional technology platforms. The
company has been accredited with multiple honors including Nanjing Key Laboratory
for AI-Aided Drug Design and Nanjing Engineering Research Center for Synthetic Biology
and Flow Chemistry. Its AI-assisted directed enzyme mutation technology was recognized
as an Advanced Cleaner Production Technology of Nanjing. The company has raised 
over 1.2 billion RMB in total financing in the past five years, winning wide recognition
from the capital market.

Going forward, adhering to the original aspiration of "The better Care, The better
Medicines", Vcare PharmaTech will continue to deepen AI-driven original innovation,
make breakthroughs in cutting-edge pharmaceutical technologies and expand its strategic
layout at home and abroad. With solid R&D strength and differentiated drug pipelines,
the company aims to deliver superior treatment solutions to patients across the 
globe and grow into a world-class innovative pharmaceutical enterprise.

**Commercial Cooperation: Strategic Development Director: Dr. Peng  [peng_yuran@vcarepharmatech.com](https://www.thailand-business-news.com/pr-news/peng_yuran@vcarepharmatech.com)

BD Director: Liam  [xu_minghua@vcarepharmatech.com](https://www.thailand-business-news.com/pr-news/xu_minghua@vcarepharmatech.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted ](http://www.prnasia.com/story/archive/4993141_CN93141_0?rand=184833)
